Compare Abeona Therapeutics Inc (ABEO) vs Global X Lithium & Battery Tech ETF (LIT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Global X Lithium & Battery Tech ETF — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while Global X Lithium & Battery Tech ETF trades at $72.05. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, Global X Lithium & Battery Tech ETF nearer its low. Which is the better fit depends on your goals.
| ABEO | LIT | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $7.23 | $91.62 |
52-Week Low | $4.17 | $39.41 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
LIT (Global X Lithium & Battery Tech ETF) trades at $76.17, down 0.47% with a bearish technical outlook. The ETF faces selling pressure from moving averages but maintains neutral oscillator readings. Recent news highlights strong momentum driven by energy storage, semiconductors, and EV demand, with the fund returning 125% from last year's lows according to 24/7 Wall Street on June 7, 2026. Key financial ratios remain undisclosed in current data.
Outlook remains mixed with technical weakness offset by strong sector catalysts. Investment opportunity lies in exposure to lithium and battery technology growth, particularly from EV and AI demand. Risks include reliance on Chinese supply chains, regulatory changes, and commodity price volatility. The upcoming dividend of $0.32 per share scheduled for July 2026 provides income potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Global X Lithium & Battery Tech ETF
LIT invests in the full lithium cycle, from mining and refining to battery production and EV manufacturing. It tracks the Solactive Global Lithium Index, with top holdings including Rio Tinto, Albemarle, and Tesla, as well as major battery makers like Samsung SDI.
Read more on LIT →
